Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer

This study is testing a combination of two targeted drugs — glumetinib and fruquintinib — in people with advanced colorectal cancer that has spread (metastatic) and whose tumors have a specific protein overactive called MET. This combination is being tested as a third-line treatment, meaning patients have already tried two prior treatments that stopped working. **You may be eligible if...** - You are 18 or older with confirmed metastatic colorectal cancer (microsatellite stable type) - Your tumor has been tested and shows MET amplification or MET protein overexpression - Your cancer progressed after two previous standard treatment regimens - You have at least one measurable tumor and are in reasonably good health - Your expected survival is at least 3 months **You may NOT be eligible if...** - Your cancer does not have MET overexpression or amplification - You have severe problems with your liver, kidneys, or heart that make you unable to tolerate the drugs - You have active infections, active autoimmune disease, or uncontrolled brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.